Evidence map›Paper›PMID 41051715›Full record

ReviewAdvances in neurobiology2025

Monoamine-Uptake Inhibitors and Pain: Antidepressant Drugs Among First-Line Treatments Against Neuropathic Pain and Fibromyalgia.

Michel Barrot, Henrico-Pio Basile, Mélanie Kremer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michel BarrotInstitut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Université de Strasbourg, Strasbourg, France. mbarrot@unistra.fr.
Henrico-Pio BasileInstitut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Université de Strasbourg, Strasbourg, France.
Mélanie KremerInstitut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Université de Strasbourg, Strasbourg, France. melaniekremer@unistra.fr.ORCID https://orcid.org/0000-0003-2814-5706

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some monoamine-uptake inhibitors are among first-line treatments for specific chronic pain conditions. It concerns tricyclic antidepressant drugs, such as amitriptyline or nortriptyline, and the more selective serotonergic and noradrenergic reuptake inhibitors, such as duloxetine. They are recommended for treating neuropathic pain, which is pain caused by a lesion or disease of the somatosensory nervous system, and fibromyalgia, which is a chronic widespread pain. Clinically, their action on pain was proposed to be independent from the one on depression. Research in animal models provided some understanding of the pain-relieving mechanism. The noradrenergic component of monoamine-uptake inhibitors appears to be critical, with the therapeutic effect likely involving targets at peripheral, spinal and supraspinal levels. At least two independent mechanisms would contribute to pain relief. One is spinal, relying on the recruitment of aminergic descending controls of pain, with a downstream key role of the α

Indexed as

Antidepressive AgentsFibromyalgiaNeuralgiaAdrenergic Uptake InhibitorsAnimalsHumansAdrenergic Uptake InhibitorsAntidepressive AgentsAntidepressantsMonoaminergic systemNeuroimmuneNeuropathic painOpioidergic system

Identifiers

PMID41051715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.